Definition and taxonomy of interval colorectal cancers: A proposal for standardising nomenclature

Gut

Volumn 64, Issue 8, 2015, Pages 1257-1267

  Sanduleanu, S ^a,b   Le Clercq, C M C ^a   Dekker, E ^c   Meijer, G A ^d   Rabeneck, L ^b   Rutter, M D ^e,f   Valori, R ^g   Young, G P ^h,i   Schoen, R E ^j  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY HOSPITAL OF NORTH TEES   (United Kingdom)

^g DURHAM UNIVERSITY   (United Kingdom)

^h GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

ⁱ FLINDERS UNIVERSITY   (Australia)

^j UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; DELPHI STUDY; FECES ANALYSIS; HIGH RISK POPULATION; HUMAN; IMMUNOCHEMISTRY; INTERVAL COLORECTAL CANCER; MODIFIED DELPHI STUDY; OCCULT BLOOD TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEX DIFFERENCE; SIGMOIDOSCOPY; STANDARDIZATION; SYSTEMATIC REVIEW; CLASSIFICATION; COLORECTAL NEOPLASMS; EARLY DIAGNOSIS; MASS SCREENING; NOMENCLATURE; PROCEDURES;

COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; HUMANS; MASS SCREENING; TERMINOLOGY AS TOPIC;

EID: 84940376470     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307992     Document Type: Article

References (79)

1. Mandel JS, Church TR, Bond J.H., et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343:1603-7.
2. Hardcastle JD, Chamberlain JO, Robinson M.H., et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348:1472-7.
3. Kronborg O, Fenger C, Olsen J., et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348:1467-71.
4. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010; 375:1624-33.
5. Segnan N, Armaroli P, Bonelli L., et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial - SCORE. J Natl Cancer Inst 2011; 103:1310-22.
6. Schoen RE, Pinsky PF, Weissfeld J.L., et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012; 366:2345-57.
7. Shaukat A, Mongin SJ, Geisser M.S., et al. Long-term mortality after screening for colorectal cancer. N Engl J Med 2013; 369:1106-14.
8. Winawer SJ, Zauber AG, Ho M.N., et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329:1977-81.
9. Brenner H, Chang-Claude J, Seiler C.M., et al. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med 2011; 154:22-30.
10. Nishihara R, Wu K, Lochhead P., et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013; 369:1095-105.
11. Baxter NN, Goldwasser MA, Paszat L.F., et al. Association of colonoscopy and death from colorectal cancer. Ann Intern Med 2009; 150:1-8.
12. Zauber AG, Winawer SJ, O'Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012; 366:687-96.
13. Rex DK, Hewett DG, Snover DC Editorial: Detection targets for colonoscopy: from variable detection to validation. Am J Gastroenterol 2010; 105:2665-9.
14. Rabeneck L, Paszat LF Circumstances in which colonoscopy misses cancer. Frontline Gastroenterol 2010; 1:52-8.
15. Hazewinkel Y, Dekker E. Colonoscopy: basic principles and novel techniques. Nat Rev Gastroenterol Hepatol 2011; 8:554-64.
16. Sanduleanu S, Masclee AM, Meijer GA Interval cancers after colonoscopy-insights and recommendations. Nat Rev Gastroenterol Hepatol 2012; 9:550-4.
17. Bressler B, Paszat LF, Chen Z, et al Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. Gastroenterology 2007; 132:96-102.
18. Singh H, Nugent Z, Demers A.A., et al. Rate and predictors of early/missed colorectal cancers after colonoscopy in manitoba: a population-based study. Am J Gastroenterol 2010; 105:2588-96.
19. Baxter NN, Sutradhar R, Forbes S.S., et al. Analysis of administrative data finds endoscopist quality measures associated with postcolonoscopy colorectal cancer. Gastroenterology 2011; 140:65-72.
20. Guittet L, Bouvier V, Mariotte N., et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 2007; 56:210-14.
21. Lieberman DA, Weiss DG, Harford W.V., et al. Five-year colon surveillance after screening colonoscopy. Gastroenterology 2007; 133:1077-85.
22. Matsuda T, Fujii T, Sano Y., et al. Five-year incidence of advanced neoplasia after initial colonoscopy in Japan: a multicenter retrospective cohort study. Jpn J Clin Oncol 2009; 39:435-42.
23. Strock P, Mossong J, Scheiden R., et al. Colorectal cancer incidence is low in patients following a colonoscopy. Dig Liver Dis 2011; 43:899-904.
24. Brenner H, Chang-Claude J, Seiler C.M., et al. Interval cancers after negative colonoscopy: population-based case-control study. Gut 2012; 61:1576-82.
25. Atkin WS, Saunders BP,; British Society for G, Association of Coloproctology for Great B, Ireland. Surveillance guidelines after removal of colorectal adenomatous polyps. Gut 2002; 51(Suppl 5):V6-9.
26. Force USPST. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149:627-37.
27. Cairns SR, Scholefield JH, Steele R.J., et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010; 59:666-89.
28. Cancer Council Australia Colonoscopy Surveillance Working Party. Clinical practice guidelines for surveillance colonoscopy - in adenoma follow-up; following curative resection of colorectal cancer; and for cancer surveillance in inflammatory bowel disease. Sydney: Cancer Council Australia. 2011.
29. Lieberman DA, Rex DK, Winawer S.J., et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2012; 143:844-57.
30. Leddin D, Enns R, Hilsden R., et al. Colorectal cancer surveillance after index colonoscopy: guidance from the Canadian Association of Gastroenterology. Can J Gastroenterol 2013; 27:224-8.
31. Nederlandse Vereniging van Maag-, Darm- en Leverartsen. Nederlandse Richtlijn Coloscopie Surveillance. 2013.
32. Milholland AV, Wheeler SG, Heieck JJ Medical assessment by a Delphi group opinion technic. N Engl J Med 1973; 288:1272-5.
33. Guyatt GH, Oxman AD, Vist G.E., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-6.
34. Haseman JH, Lemmel GT, Rahmani E.Y., et al. Failure of colonoscopy to detect colorectal cancer: evaluation of 47 cases in 20 hospitals. Gastrointest Endosc 1997; 45:451-5.
35. Baxter NN, Warren JL, Barrett M.J., et al. Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty. J Clin Oncol 2012; 30:2664-9.
36. Cooper GS, Xu F, Barnholtz Sloan JS, et al. Prevalence and predictors of interval colorectal cancers in medicare beneficiaries. Cancer 2012; 118:3044-52.
37. Farrar WD, Sawhney MS, Nelson D.B., et al. Colorectal cancers found after a complete colonoscopy. Clin Gastroenterol Hepatol 2006; 4:1259-64.
38. Huang Y, Gong W, Su B., et al. Risk and cause of interval colorectal cancer after colonoscopic polypectomy. Digestion 2012; 86:148-54.
39. le Clercq C.M., Bouwens MW, Rondagh E.J., et al. Postcolonoscopy colorectal cancers are preventable: a population-based study. Gut 2014; 63:957-63.
40. Horiuchi A, Nakayama Y, Kajiyama M., et al. Invasive colorectal cancer within 5 years of negative colonoscopy in a Japanese population. Colorectal Dis 2012; 14:1090-4.
41. Samadder NJ, Curtin K, Tuohy T.M., et al. Characteristics of missed or interval colorectal cancer and patient survival: a population-based study. Gastroenterology 2014; 146:950-60.
42. Erichsen R, Baron JA, Stoffel E.M., et al. Characteristics and survival of interval and sporadic colorectal cancer patients: a nationwide population-based cohort study. Am J Gastroenterol 2013; 108:1332-40.
43. Brenner H, Altenhofen L, Katalinic A., et al. Sojourn time of preclinical colorectal cancer by sex and age: estimates from the German national screening colonoscopy database. Am J Epidemiol 2011; 174:1140-6.
44. Pabby A, Schoen RE, Weissfeld J.L., et al. Analysis of colorectal cancer occurrence during surveillance colonoscopy in the dietary Polyp Prevention Trial. Gastrointest Endosc 2005; 61:385-91.
45. Robertson DJ, Lieberman DA, Winawer S.J., et al. Colorectal cancers soon after colonoscopy: a pooled multicohort analysis. Gut 2014; 63:949-56.
46. Rex DK, Bond JH, Feld AD Medical-legal risks of incident cancers after clearing colonoscopy. Am J Gastroenterol 2001; 96:952-7.
47. Lakoff J, Paszat LF, Saskin R, et al Risk of developing proximal versus distal colorectal cancer after a negative colonoscopy: a population-based study. Clin Gastroenterol Hepatol 2008; 6:1117-21; quiz 064.
48. Kaminski MF, Regula J, Kraszewska E., et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med 2010; 362:1795-803.
49. Corley DA, Jensen CD, Marks A.R., et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 2014; 370:1298-306.
50. Leaper M, Johnston MJ, Barclay M, et al Reasons for failure to diagnose colorectal carcinoma at colonoscopy. Endoscopy 2004; 36:499-503.
51. Kahi CJ, Imperiale TF, Juliar B.E., et al. Effect of screening colonoscopy on colorectal cancer incidence and mortality. Clin Gastroenterol Hepatol 2009; 7: 770-5; quiz 11.
52. Ferrández A., Navarro M, Diez M., et al. Risk factors for advanced lesions undetected at prior colonoscopy: not always poor preparation. Endoscopy 2010; 42:1071-6.
53. Robertson DJ, Greenberg ER, Beach M, et al Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology 2005; 129:34-41.
54. Leung K, Pinsky P, Laiyemo A.O., et al. Ongoing colorectal cancer risk despite surveillance colonoscopy: the Polyp Prevention Trial Continued Follow-up Study. Gastrointest Endosc 2010; 71:111-17.
55. Sawhney MS, Farrar WD, Gudiseva S, et al Microsatellite instability in interval colon cancers. Gastroenterology 2006; 131:1700-5.
56. Arain MA, Sawhney M, Sheikh S., et al. CIMP status of interval colon cancers: another piece to the puzzle. Am J Gastroenterol 2010; 105:1189-95.
57. Hoff G, Grotmol T, Skovlund E., et al. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ 2009; 338: b1846.
58. Schoen RE, Pinsky PF, Weissfeld J.L., et al. Colorectal cancers not detected by screening flexible sigmoidoscopy in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Gastrointest Endosc 2012; 75:612-20.
59. Rogal SS, Pinsky PF, Schoen RE Relationship between detection of adenomas by flexible sigmoidoscopy and interval distal colorectal cancer. Clin Gastroenterol Hepatol 2013; 11:73-8.
60. Fraser CG, Allison JE, Halloran S.P., et al. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J Natl Cancer Inst 2012; 104:810-14.
61. Steele RJ, McClements P, Watling C., et al. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site. Gut 2012; 61:576-81.
62. Denters MJ, Deutekom M, Bossuyt P.M., et al. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer. Gastroenterology 2012; 142:497-504.
63. van Roon A.H., Goede SL, van Ballegooijen M, et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut 2013; 62:409-15.
64. Gill MD, Bramble MG, Rees C.J., et al. Comparison of screen-detected and interval colorectal cancers in the Bowel Cancer Screening Programme. Br J Cancer 2012; 107:417-21.
65. IARC. Handbooks of cancer prevention: cervix cancer screening. Lyon: IARC Press, 2005.
66. Atkin WS, Valori R, Kuipers E.J., et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition - Colonoscopic surveillance following adenoma removal. Endoscopy 2012; 44(suppl 3): SE151-63.
67. Moss S, Ancelle-Park R, Brenner H., et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition - Evaluation and interpretation of screening outcomes. Endoscopy 2012; 44(Suppl 3): SE49-64.
68. Imperiale TF, Glowinski EA, Lin-Cooper C, et al. Five-year risk of colorectal neoplasia after negative screening colonoscopy. N Engl J Med 2008; 359: 1218-24.
69. Scholefield JH, Moss SM, Mangham C.M., et al. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut 2012; 61:1036-40.
70. Crotta S, Segnan N, Paganin S., et al. High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test. Clin Gastroenterol Hepatol 2012; 10:633-8.
71. de Wijkerslooth T.R., Stoop EM, Bossuyt P.M., et al. Immunochemical Fecal Occult Blood Testing Is Equally Sensitive for Proximal and Distal Advanced Neoplasia. Am J Gastroenterol 2012; 107:1570-8.
72. Morris EJ, Whitehouse LE, Farrell T, et al A retrospective observational study examining the characteristics and outcomes of tumours diagnosed within and without of the English NHS Bowel Cancer Screening Programme. Br J Cancer 2012; 107:757-64.
73. Rozen P, Liphshitz I, Barchana M. Follow-up of patients undergoing both semiquantitated immunochemical fecal occult blood and colonoscopy examinations. Eur J Cancer Prev 2012; 21:247-53.
74. Levi Z, Birkenfeld S, Vilkin A., et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. Int J Cancer 2011; 128:2415-24.
75. Zorzi M, Fedato C, Grazzini G., et al. High sensitivity of five colorectal screening programmes with faecal immunochemical test in the Veneto Region, Italy. Gut 2011; 60:944-9.
76. Lisi D, Hassan C, Crespi M. Participation in colorectal cancer screening with FOBT and colonoscopy: an Italian, multicentre, randomized population study. Dig Liver Dis 2010; 42:371-6.
77. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010; 59:62-8.
78. Paimela H, Malila N, Palva T., et al. Early detection of colorectal cancer with faecal occult blood test screening. Br J Surg 2010; 97:1567-71.
79. Faivre J, Dancourt V, Lejeune C., et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 2004; 126:1674-80.